



BioBridge® was founded in 1989 in Cambridge UK. We focus on understanding and overcoming barriers to commercialisation for innovation in life science technologies and products and our work spans the entire product chain from discovery development to market entry. Our clients - companies, individuals, HEIs and public bodies - are in healthcare, biotechnology, medical devices, biomaterials, agricultural resources, animal health and food.

Current projects demonstrate our breadth and include:

- compliance and safety issues with live animal sources for medical biomaterial products
- identifying and analysing licensable products for a Japanese pharmaceutical company, introducing potential licensors and partners
- project monitoring and support for publicly-funded projects in industrial biotechnology
- regulatory strategy and practical assistance for a novel nutritional additive for petfoods
- analysis of the prospects for a business start-up in metagenomic products and services
- knowledge transfer manager in the UK's Bioscience for Business Knowledge Transfer Network, bringing manufacturing companies and sources of new technology together, to encourage greater use of bioprocesses, biomass and renewable bioresources

In other work, we have:

- moved technology prospects, start-ups and investment prospects forward:
 - due diligence for investors in a novel bio-based high throughput screen company, novel cell-based treatments for Alzheimer's disease & bone dystrophies, a Scottish biomaterials company, a nutrigenomic lifestyle services company, a Northern Ireland animal health company, and other targets for acquisition and flotation
 - technology and market analyses of university inventions including biotechnology research reagents, a novel microfluidics development, novel ocular lenses, innovations in biomanufacturing measurements, medical applications of terahertz technologies
 - project monitoring and support for publicly-funded projects in biomaterials and medical devices

- enhanced the grasp of challenges for business growth and market management of innovations:

- prospects for biopharmaceuticals from transgenic plants
- market dynamics in Europe for novel cell-based therapies and novel pharmaceuticals for asthma and burns treatment
- EU distributor-finding programme for cardiac monitoring company
- regulatory dynamics in the EU for foetal stem-cell based products and the status of tissue engineering and regenerative medicine in Japan
- regulatory issues in Europe for GMOs in food, feed, farming and diagnostics
- European strategy for healthcare biomaterials and biotech-device products

20 years of turning innovation into action!

BioBridge Ltd, 45 St Barnabas Road, Cambridge CB1 2BX UK
tel +44 1223 566850 mobile +44 776 776 6339
email milloydevans@biobridge.co.uk, web www.biobridge.co.uk

undertaken larger-scale strategy and science-management projects as lead or team:
Technology Translator for the UK's BlueMicrobe marine biodiversity Knowledge Transfer Network
profile of the UK's marine biotechnology research and commercial activities, assessment of competitive position and construction of a strategy for technological and economic development, for the *Foresight* Marine Panel's Marine Biotechnology Group.
IP and development advice during management of the 19-project European Biomaterials Network for the EC, organising conferences and seminars, networking professionals together, facilitating communication between projects, auditing projects
profile of Scotland's activities in biomaterials research and commercialisation, assessment of competitive position and prospects for development, for a Scottish Enterprise LEC
UK regional biotechnology trend analysis for a Japanese government body.

Mr Meredith Lloyd-Evans, Managing Director of BioBridge Ltd, began his career as a veterinarian, then joined SmithKline Animal Health UK Ltd and became the Technical Director UK and Co-ordinator for veterinary pharmaceutical product development Europe. He has worked in technology transfer and licensing with the British Technology Group, responsible for a portfolio of inventors, patents, projects and commercial licenses in biotechnology and biomaterials as well as animal health. He worked briefly for the technology consultancy PA before setting up BioBridge. The company has evolved from a sole tradership through partnership to a limited company with a well-established network of associates. BioBridge Associates includes colleagues of similar experience and effectiveness from Japan, USA and Europe who are called on when additional resource and expertise is needed to provide the service that our clients have specified with us.

He has represented UK frequently in missions and conference panels in USA, Europe, Korea and Japan, in areas including health technologies, industrial biotechnology, agricultural biotechnology and bioclusters. Throughout the past 30 years, he has written and published numerous articles and industry reports and has planned, chaired or presented at a wide range of events.

He is a member of an investment and mentoring group that exists to support start-ups by recent ex-pupils of Manchester Grammar School. He is an assessor for proposals to the EU's Framework Programmes and to the UK's Technology Strategy Board programme and a monitor for funded projects. He is a trustee of the University of Cambridge Veterinary School Trust.

For further information, contact Meredith, or BioBridge's PA Mrs Sue Addison (admin@biobridge.co.uk).

BioBridge/profgen2008/1008

20 years of turning innovation into action!
BioBridge Ltd, 45 St Barnabas Road, Cambridge CB1 2BX UK
tel +44 1223 566850 mobile +44 776 776 6339
email mllloyddevans@biobridge.co.uk, web www.biobridge.co.uk